DIOVAN- valsartan tablet USA - engelska - NLM (National Library of Medicine)

diovan- valsartan tablet

novartis pharmaceuticals corporation - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint nation

DIOVAN- valsartan tablet USA - engelska - NLM (National Library of Medicine)

diovan- valsartan tablet

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

DIOVAN- valsartan tablet USA - engelska - NLM (National Library of Medicine)

diovan- valsartan tablet

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

Valsartan Teva 160 mg filmomh. tabl. Belgien - nederländska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

valsartan teva 160 mg filmomh. tabl.

teva pharma belgium sa-nv - valsartan 160 mg - filmomhulde tablet - 160 mg - valsartan 160 mg - valsartan

Valsartan + Hidroclorotiazida Aurovitas 160 mg + 12.5 mg Comprimido revestido por película Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

valsartan + hidroclorotiazida aurovitas 160 mg + 12.5 mg comprimido revestido por película

generis farmacêutica, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 12.5 mg - valsartan 160 mg ; hidroclorotiazida 12.5 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

Valsartan + Hidroclorotiazida Aurovitas 160 mg + 25 mg Comprimido revestido por película Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

valsartan + hidroclorotiazida aurovitas 160 mg + 25 mg comprimido revestido por película

generis farmacêutica, s.a. - valsartan + hidroclorotiazida - comprimido revestido por película - 160 mg + 25 mg - valsartan 160 mg ; hidroclorotiazida 25 mg - valsartan and diuretics - genérico - duração do tratamento: longa duração

DIOVAN 160MG TABLETS Comprimé Kanada - franska - Health Canada

diovan 160mg tablets comprimé

novartis pharmaceuticals canada inc - valsartan - comprimé - 160mg - valsartan 160mg - angiotensin ii receptor antagonists

Valsartan Teva 160 mg compr. pellic. Belgien - franska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

valsartan teva 160 mg compr. pellic.

teva pharma belgium sa-nv - valsartan 160 mg - comprimé pelliculé - 160 mg - valsartan 160 mg - valsartan

DIOVAN 160MG TABLETS Kanada - engelska - Health Canada

diovan 160mg tablets

novartis pharmaceuticals canada inc - valsartan - tablet - 160mg - valsartan 160mg - angiotensin ii receptor antagonists

DIOVAN HCT- valsartan and hydrochlorothiazide tablet, film coated USA - engelska - NLM (National Library of Medicine)

diovan hct- valsartan and hydrochlorothiazide tablet, film coated

pd-rx pharmaceuticals, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education